Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$121.9 million.

  • Altimmune's Net Cash Flow fell 37506.72% to -$121.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.8 million, marking a year-over-year increase of 15374.14%. This contributed to the annual value of -$98.2 million for FY2024, which is 50866.53% down from last year.
  • Latest data reveals that Altimmune reported Net Cash Flow of -$121.9 million as of Q3 2025, which was down 37506.72% from $134.0 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Net Cash Flow ranged from a high of $134.0 million in Q2 2025 and a low of -$121.9 million during Q3 2025
  • Its 5-year average for Net Cash Flow is -$2.9 million, with a median of -$6.4 million in 2023.
  • As far as peak fluctuations go, Altimmune's Net Cash Flow soared by 137090.11% in 2021, and later plummeted by 120289.09% in 2022.
  • Altimmune's Net Cash Flow (Quarter) stood at $15.4 million in 2021, then plummeted by 206.03% to -$16.4 million in 2022, then surged by 394.86% to $48.3 million in 2023, then plummeted by 88.7% to $5.5 million in 2024, then plummeted by 2335.31% to -$121.9 million in 2025.
  • Its Net Cash Flow was -$121.9 million in Q3 2025, compared to $134.0 million in Q2 2025 and $12.2 million in Q1 2025.